Turkey’s health minister has announced the launch of a national initiative to develop and produce domestically manufactured weight-loss injections, marking a significant shift in the country’s approach to obesity treatment and pharmaceutical self-reliance. Speaking during a live broadcast on CNN Türk, Health Minister Kemal Memişoğlu outlined Turkey’s strategy to reduce dependence on imported anti-obesity medications by advancing local production of glucagon-like peptide-1 (GLP-1) receptor agonists, the class of drugs commonly known as weight-loss injections.
The announcement comes amid growing global demand for medications like semaglutide and tirzepatide, which have shown efficacy in clinical trials for weight management but remain costly and subject to supply constraints. Memişoğlu emphasized that Turkey aims to not only meet domestic needs but also position itself as a regional producer of these therapeutics, citing ongoing investments in biopharmaceutical infrastructure and regulatory pathways designed to accelerate approval and distribution.
According to verified statements from the minister’s CNN Türk interview, Turkey has already completed construction of 27 city hospitals, with 12 additional facilities currently under construction in provinces including Trabzon, Şanlıurfa, Samsun, and Rize. These bin-yataklı (thousand-bed) hospitals are part of a broader healthcare expansion plan intended to strengthen the nation’s medical capacity, including specialized departments equipped to handle metabolic disorders and administer advanced therapies like GLP-1-based treatments under medical supervision.
The minister further highlighted the evolving role of family physicians in Turkey’s preventive healthcare model, noting that revised regulations enacted in November have empowered the country’s 31,000 family doctors to serve as first points of contact for patients seeking weight management interventions. Under this system, family physicians conduct preliminary screenings, monitor chronic disease risk factors, and coordinate referrals to specialist care when necessary — a process designed to ensure that any pharmacological treatment, including future domestically produced weight-loss injections, is administered within a framework of clinical oversight and patient safety.
Memişoğlu also disclosed that national health screenings have evaluated 42 million individuals for chronic disease risk, identifying 10 million as high-risk and providing follow-up care and treatment for 5 million of those cases. These efforts, he stated, are integrated with hospital workload management, as family doctors help triage patients and reduce unnecessary admissions by managing early-stage conditions through personalized care plans and direct communication with specialists.
While the minister did not disclose specific timelines for the rollout of locally produced weight-loss injections, he confirmed that research and development efforts are underway in collaboration with Turkish pharmaceutical firms and academic institutions. The initiative aligns with Turkey’s broader goal of increasing domestic production of essential medicines, a priority underscored by recent global shortages and geopolitical vulnerabilities in pharmaceutical supply chains.
Health experts note that GLP-1 receptor agonists function by mimicking a hormone that regulates appetite and insulin secretion, leading to reduced food intake and improved glycemic control. Originally developed for type 2 diabetes treatment, these medications have demonstrated significant weight loss outcomes in obese and overweight populations, prompting regulatory approvals for obesity management in multiple countries. But, their use requires medical supervision due to potential side effects, including gastrointestinal disturbances and, in rare cases, more serious complications necessitating careful patient selection and monitoring.
The Turkish Medicines and Medical Devices Agency (TİTCK) oversees the approval and regulation of all pharmaceutical products in the country, including novel therapeutics like domestically produced GLP-1 analogs. Any locally manufactured weight-loss injection would need to undergo rigorous preclinical and clinical testing to meet international standards for safety, efficacy, and quality before receiving market authorization — a process that typically spans several years and involves phased trials involving thousands of participants.
Officials have not yet disclosed which specific molecules Turkey intends to produce, whether biosimilar versions of existing patented drugs or novel formulations under development. Patent protections on leading GLP-1 therapies remain in force in many jurisdictions, meaning that any domestic production would need to navigate intellectual property frameworks, potentially through licensing agreements or post-patent manufacturing once exclusivity periods expire.
Despite the promise of pharmacological aids, public health authorities in Turkey continue to emphasize lifestyle modification as the cornerstone of sustainable weight management. Minister Memişoğlu reiterated during his interview that the healthiest approach to weight loss remains natural methods — balanced nutrition, regular physical activity, and behavioral support — cautioning against the perception of weight-loss injections as quick fixes or cosmetic solutions.
This stance reflects broader medical consensus that while anti-obesity medications can be effective tools for certain individuals, they are most beneficial when combined with comprehensive lifestyle programs and long-term behavioral support. The World Health Organization and numerous clinical guidelines recommend that pharmacotherapy be considered only after unsuccessful attempts at lifestyle intervention, particularly for patients with a body mass index (BMI) of 30 or higher, or 27 or higher with obesity-related comorbidities.
As Turkey advances its domestic pharmaceutical capabilities, the integration of locally produced weight-loss treatments into public health programs will depend on pricing policies, reimbursement decisions by the Social Security Institution (SGK), and clinical guidelines issued by professional medical associations. Transparent reporting on safety data, real-world effectiveness, and equitable access will be critical to maintaining public trust and ensuring that these therapies serve those with genuine medical need rather than being misused for non-medical weight loss.
The next official update on Turkey’s domestic production timeline for weight-loss injections is expected during the Health Ministry’s quarterly progress briefing, scheduled for late May 2026, where officials typically report on pharmaceutical manufacturing milestones, regulatory approvals, and healthcare infrastructure developments.
For readers seeking authoritative information on obesity treatment options, medication safety, or public health initiatives in Turkey, the World Today Journal recommends consulting official sources including the Turkish Ministry of Health website, the Turkish Medicines and Medical Devices Agency (TİTCK), and peer-reviewed publications from institutions such as Hacettepe University Institute of Public Health and Istanbul University-Cerrahpaşa Faculty of Medicine.
We encourage informed discussion on this important public health topic. Share your thoughts in the comments below and help spread accurate, evidence-based information by sharing this article with others who may benefit from reliable medical insights.